Cargando…
Shigella-specific antibodies in the first year of life among Zambian infants: A longitudinal cohort study
INTRODUCTION: Shigellosis, is a leading cause of moderate-to-severe diarrhoea and related mortality in young children in low and middle income countries (LMICs). Knowledge on naturally acquired immunity can support the development of Shigella candidate vaccines mostly needed in LMICs. We aimed to qu...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8158915/ https://www.ncbi.nlm.nih.gov/pubmed/34043697 http://dx.doi.org/10.1371/journal.pone.0252222 |
_version_ | 1783699968167510016 |
---|---|
author | Chisenga, Caroline C. Bosomprah, Samuel Simuyandi, Michelo Mwila-Kazimbaya, Katayi Chilyabanyama, Obvious N. Laban, Natasha M. Bialik, Anya Asato, Valeria Meron-Sudai, Shiri Frankel, Gad Cohen, Daniel Chilengi, Roma |
author_facet | Chisenga, Caroline C. Bosomprah, Samuel Simuyandi, Michelo Mwila-Kazimbaya, Katayi Chilyabanyama, Obvious N. Laban, Natasha M. Bialik, Anya Asato, Valeria Meron-Sudai, Shiri Frankel, Gad Cohen, Daniel Chilengi, Roma |
author_sort | Chisenga, Caroline C. |
collection | PubMed |
description | INTRODUCTION: Shigellosis, is a leading cause of moderate-to-severe diarrhoea and related mortality in young children in low and middle income countries (LMICs). Knowledge on naturally acquired immunity can support the development of Shigella candidate vaccines mostly needed in LMICs. We aimed to quantify Shigella-specific antibodies of maternal origin and those naturally acquired in Zambian infants. METHODS: Plasma samples collected from infants at age 6, 14 and 52-weeks were tested for Shigella (S. sonnei and S. flexneri 2a) lipopolysaccharide (LPS) antigen specific immunoglobulin G (IgG) and A (IgA) by enzyme-linked immunosorbent assay. RESULTS: At 6 weeks infant age, the IgG geometric mean titres (GMT) against S. sonnei (N = 159) and S. flexneri 2a (N = 135) LPS were 311 (95% CI 259–372) and 446 (95% CI 343–580) respectively. By 14 weeks, a decline in IgG GMT was observed for both S. sonnei to 104 (95% CI 88–124), and S. flexneri 2a to 183 (95% CI 147–230). Both S. sonnei and S. flexneri 2a specific IgG GMT continued to decrease by 52 weeks infant age when compared to 6 weeks. In 27% and 8% of infants a significant rise in titre (4 fold and greater) against S. flexneri 2a and S. sonnei LPS, respectively, was detected between the ages of 14 and 52 weeks. IgA levels against both species LPS were very low at 6 and 14 weeks and raised significantly against S. flexneri 2a and S. sonnei LPS in 29% and 10% of the infants, respectively. CONCLUSION: In our setting, transplacental IgG anti-Shigella LPS is present at high levels in early infancy, and begins to decrease by age 14 weeks. Our results are consistent with early exposure to Shigella and indicate naturally acquired IgG and IgA antibodies to S. flexneri 2a and S. sonnei LPS in part of infants between 14 and 52 weeks of age. These results suggest that a potential timing of vaccination would be after 14 and before 52 weeks of age to ensure early infant protection against shigellosis. |
format | Online Article Text |
id | pubmed-8158915 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-81589152021-06-09 Shigella-specific antibodies in the first year of life among Zambian infants: A longitudinal cohort study Chisenga, Caroline C. Bosomprah, Samuel Simuyandi, Michelo Mwila-Kazimbaya, Katayi Chilyabanyama, Obvious N. Laban, Natasha M. Bialik, Anya Asato, Valeria Meron-Sudai, Shiri Frankel, Gad Cohen, Daniel Chilengi, Roma PLoS One Research Article INTRODUCTION: Shigellosis, is a leading cause of moderate-to-severe diarrhoea and related mortality in young children in low and middle income countries (LMICs). Knowledge on naturally acquired immunity can support the development of Shigella candidate vaccines mostly needed in LMICs. We aimed to quantify Shigella-specific antibodies of maternal origin and those naturally acquired in Zambian infants. METHODS: Plasma samples collected from infants at age 6, 14 and 52-weeks were tested for Shigella (S. sonnei and S. flexneri 2a) lipopolysaccharide (LPS) antigen specific immunoglobulin G (IgG) and A (IgA) by enzyme-linked immunosorbent assay. RESULTS: At 6 weeks infant age, the IgG geometric mean titres (GMT) against S. sonnei (N = 159) and S. flexneri 2a (N = 135) LPS were 311 (95% CI 259–372) and 446 (95% CI 343–580) respectively. By 14 weeks, a decline in IgG GMT was observed for both S. sonnei to 104 (95% CI 88–124), and S. flexneri 2a to 183 (95% CI 147–230). Both S. sonnei and S. flexneri 2a specific IgG GMT continued to decrease by 52 weeks infant age when compared to 6 weeks. In 27% and 8% of infants a significant rise in titre (4 fold and greater) against S. flexneri 2a and S. sonnei LPS, respectively, was detected between the ages of 14 and 52 weeks. IgA levels against both species LPS were very low at 6 and 14 weeks and raised significantly against S. flexneri 2a and S. sonnei LPS in 29% and 10% of the infants, respectively. CONCLUSION: In our setting, transplacental IgG anti-Shigella LPS is present at high levels in early infancy, and begins to decrease by age 14 weeks. Our results are consistent with early exposure to Shigella and indicate naturally acquired IgG and IgA antibodies to S. flexneri 2a and S. sonnei LPS in part of infants between 14 and 52 weeks of age. These results suggest that a potential timing of vaccination would be after 14 and before 52 weeks of age to ensure early infant protection against shigellosis. Public Library of Science 2021-05-27 /pmc/articles/PMC8158915/ /pubmed/34043697 http://dx.doi.org/10.1371/journal.pone.0252222 Text en © 2021 Chisenga et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Chisenga, Caroline C. Bosomprah, Samuel Simuyandi, Michelo Mwila-Kazimbaya, Katayi Chilyabanyama, Obvious N. Laban, Natasha M. Bialik, Anya Asato, Valeria Meron-Sudai, Shiri Frankel, Gad Cohen, Daniel Chilengi, Roma Shigella-specific antibodies in the first year of life among Zambian infants: A longitudinal cohort study |
title | Shigella-specific antibodies in the first year of life among Zambian infants: A longitudinal cohort study |
title_full | Shigella-specific antibodies in the first year of life among Zambian infants: A longitudinal cohort study |
title_fullStr | Shigella-specific antibodies in the first year of life among Zambian infants: A longitudinal cohort study |
title_full_unstemmed | Shigella-specific antibodies in the first year of life among Zambian infants: A longitudinal cohort study |
title_short | Shigella-specific antibodies in the first year of life among Zambian infants: A longitudinal cohort study |
title_sort | shigella-specific antibodies in the first year of life among zambian infants: a longitudinal cohort study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8158915/ https://www.ncbi.nlm.nih.gov/pubmed/34043697 http://dx.doi.org/10.1371/journal.pone.0252222 |
work_keys_str_mv | AT chisengacarolinec shigellaspecificantibodiesinthefirstyearoflifeamongzambianinfantsalongitudinalcohortstudy AT bosomprahsamuel shigellaspecificantibodiesinthefirstyearoflifeamongzambianinfantsalongitudinalcohortstudy AT simuyandimichelo shigellaspecificantibodiesinthefirstyearoflifeamongzambianinfantsalongitudinalcohortstudy AT mwilakazimbayakatayi shigellaspecificantibodiesinthefirstyearoflifeamongzambianinfantsalongitudinalcohortstudy AT chilyabanyamaobviousn shigellaspecificantibodiesinthefirstyearoflifeamongzambianinfantsalongitudinalcohortstudy AT labannatasham shigellaspecificantibodiesinthefirstyearoflifeamongzambianinfantsalongitudinalcohortstudy AT bialikanya shigellaspecificantibodiesinthefirstyearoflifeamongzambianinfantsalongitudinalcohortstudy AT asatovaleria shigellaspecificantibodiesinthefirstyearoflifeamongzambianinfantsalongitudinalcohortstudy AT meronsudaishiri shigellaspecificantibodiesinthefirstyearoflifeamongzambianinfantsalongitudinalcohortstudy AT frankelgad shigellaspecificantibodiesinthefirstyearoflifeamongzambianinfantsalongitudinalcohortstudy AT cohendaniel shigellaspecificantibodiesinthefirstyearoflifeamongzambianinfantsalongitudinalcohortstudy AT chilengiroma shigellaspecificantibodiesinthefirstyearoflifeamongzambianinfantsalongitudinalcohortstudy |